Michelle Finnegan

2.3k total citations · 3 hit papers
43 papers, 1.6k citations indexed

About

Michelle Finnegan is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Surgery. According to data from OpenAlex, Michelle Finnegan has authored 43 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Psychiatry and Mental health, 13 papers in Pathology and Forensic Medicine and 10 papers in Surgery. Recurrent topics in Michelle Finnegan's work include Migraine and Headache Studies (32 papers), Botulinum Toxin and Related Neurological Disorders (10 papers) and Neurological Disorders and Treatments (8 papers). Michelle Finnegan is often cited by papers focused on Migraine and Headache Studies (32 papers), Botulinum Toxin and Related Neurological Disorders (10 papers) and Neurological Disorders and Treatments (8 papers). Michelle Finnegan collaborates with scholars based in United States, United Kingdom and Germany. Michelle Finnegan's co-authors include Joel M. Trugman, Richard B. Lipton, Jessica Ailani, Sherwood Burge, Christopher Pickering, Kaifeng Lu, David W. Dodick, Armin Szegedi, Lawrence Severt and Peter J. Goadsby and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Michelle Finnegan

41 papers receiving 1.5k citations

Hit Papers

Ubrogepant for the Treatment of Migraine 2019 2026 2021 2023 2019 2021 2023 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ubrogepant for the Treatment of Migraine
    2019 253 citations David W. Dodick, Richard B. Lipton et al. New England Journal of Medicine profile →
  2. Atogepant for the Preventive Treatment of Migraine
    2021 194 citations Jessica Ailani, Richard B. Lipton et al. New England Journal of Medicine profile →
  3. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial
    2023 75 citations Patricia Pozo‐Rosich, Jessica Ailani et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michelle Finnegan United States 17 1.1k 698 411 285 154 43 1.6k
Yu‐Kai Lin Taiwan 19 274 0.3× 73 0.1× 258 0.6× 248 0.9× 49 0.3× 74 993
Jiunn‐Tay Lee Taiwan 21 447 0.4× 158 0.2× 245 0.6× 16 0.1× 161 1.0× 119 1.4k
Paola Caruso Italy 20 134 0.1× 145 0.2× 173 0.4× 26 0.1× 173 1.1× 65 1.2k
Dong Yeob Lee South Korea 19 296 0.3× 729 1.0× 155 0.4× 67 0.2× 63 0.4× 64 1.5k
Clive Brown Germany 18 50 0.0× 98 0.1× 229 0.6× 53 0.2× 74 0.5× 33 1.1k
Sara Schramm Germany 12 273 0.3× 143 0.2× 94 0.2× 61 0.2× 17 0.1× 47 516
Pablo Irimia Spain 21 615 0.6× 393 0.6× 274 0.7× 7 0.0× 132 0.9× 109 1.4k
Ron Munger United States 12 352 0.3× 29 0.0× 395 1.0× 39 0.1× 242 1.6× 20 2.1k
Nicholas J. Heyer United States 22 60 0.1× 110 0.2× 67 0.2× 611 2.1× 234 1.5× 32 1.3k
Helena Martynowicz Poland 24 71 0.1× 62 0.1× 869 2.1× 108 0.4× 95 0.6× 117 1.6k

Countries citing papers authored by Michelle Finnegan

Since Specialization
Citations

This map shows the geographic impact of Michelle Finnegan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Finnegan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Finnegan more than expected).

Fields of papers citing papers by Michelle Finnegan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Finnegan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Finnegan. The network helps show where Michelle Finnegan may publish in the future.

Co-authorship network of co-authors of Michelle Finnegan

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Finnegan. A scholar is included among the top collaborators of Michelle Finnegan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Finnegan. Michelle Finnegan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ashina, Messoud, Stewart J. Tepper, Uwe Reuter, et al.. (2023). Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial. Headache The Journal of Head and Face Pain. 63(1). 79–88. 36 indexed citations
2.
Pozo‐Rosich, Patricia, Jessica Ailani, Messoud Ashina, et al.. (2023). Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial (S47.005). Neurology. 100(17_supplement_2). 4 indexed citations
3.
Goadsby, Peter J., Jessica Ailani, David W. Dodick, et al.. (2023). Efficacy of ubrogepant for the treatment of migraine symptoms during the prodrome (premonitory phase): Results from the prodrome trial. Journal of the Neurological Sciences. 455. 121630–121630. 3 indexed citations
4.
Pozo‐Rosich, Patricia, Jessica Ailani, Messoud Ashina, et al.. (2023). Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 402(10404). 775–785. 75 indexed citations breakdown →
5.
Schwedt, Todd J., Richard B. Lipton, Peter J. Goadsby, et al.. (2023). Characterizing Prodrome (Premonitory Phase) in Migraine: Results From the PRODROME Trial Screening Period (S41.009). Neurology. 100(17_supplement_2). 3 indexed citations
6.
7.
Ashina, Messoud, Stewart J. Tepper, Uwe Reuter, et al.. (2022). Atogepant 60 mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-Label Extension Trial (P1-2.001). Neurology. 98(18_supplement). 1 indexed citations
8.
9.
10.
Ashina, Messoud, Stewart J. Tepper, Uwe Reuter, et al.. (2021). Long-term Safety and Tolerability of Atogepant 60 mg Following Once Daily Dosing Over 1 Year for the Preventive Treatment of Migraine (2664). Neurology. 96(15_supplement). 5 indexed citations
11.
Ailani, Jessica, Richard B. Lipton, Peter J. Goadsby, et al.. (2021). Atogepant for the Preventive Treatment of Migraine. New England Journal of Medicine. 385(8). 695–706. 194 indexed citations breakdown →
12.
Ashina, Messoud, SJ Tepper, Uwe Reuter, et al.. (2021). P.030 Long-term Safety and Tolerability of Atogepant 60 mg Following Once-Daily Dosing Over 1 Year for the Preventive Treatment of Migraine. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 48(s3). S28–S29. 2 indexed citations
13.
Trugman, Joel M., Jessica Ailani, Susan Hutchinson, et al.. (2020). Efficacy Is Maintained With Long-term Intermittent Use of Ubrogepant for the Acute Treatment of Migraine (111). Neurology. 94(15_supplement). 2 indexed citations
14.
Ailani, Jessica, Andrew Blumenfeld, Michelle Finnegan, et al.. (2020). An Optional Second Dose of Ubrogepant is Effective in Achieving 2-Hour Pain Freedom in the Acute Treatment of Migraine (166). Neurology. 94(15_supplement). 9 indexed citations
15.
Trugman, Joel M., David W. Dodick, Jessica Ailani, et al.. (2019). Efficacy, Safety, and Tolerability of Ubrogepant for the Acute Treatment of Migraine: Results From a Single-Attack Phase 3 Study, ACHIEVE II (S38.008). Neurology. 92(15_supplement). 14 indexed citations
16.
Finnegan, Michelle, David Russell‐Jones, S. Neill, et al.. (1989). Vasulitis Complicating Cystic Fibrosis. QJM. 72(267). 609–21. 42 indexed citations
17.
18.
Burge, Sherwood, et al.. (1985). Occupational asthma in a factory with a contaminated humidifier.. Thorax. 40(4). 248–254. 46 indexed citations
19.
Finnegan, Michelle & E. Brian Faragher. (1985). Amiodarone and chronic lung fibrosis. Postgraduate Medical Journal. 61(716). 497–499. 4 indexed citations
20.
Finnegan, Michelle, Christopher Pickering, & Sherwood Burge. (1984). The sick building syndrome: prevalence studies.. BMJ. 289(6458). 1573–1575. 268 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yu‐Kai Lin Breakdown of academic impact, for papers by Jiunn‐Tay Lee Breakdown of academic impact, for papers by Paola Caruso Breakdown of academic impact, for papers by Dong Yeob Lee Breakdown of academic impact, for papers by Clive Brown Breakdown of academic impact, for papers by Sara Schramm Breakdown of academic impact, for papers by Pablo Irimia Breakdown of academic impact, for papers by Ron Munger Breakdown of academic impact, for papers by Nicholas J. Heyer Breakdown of academic impact, for papers by Helena Martynowicz
Rankless by CCL
2026